Xenon Pharmaceuticals (XENE) executive compensation, 2026 proxy

Ian Mortimer, President and Chief Executive Officer, was paid $9.2M in 2025, down 6% from $9.8M the year before. The CEO-to-median-employee pay ratio was 37:1, on median employee pay of $246,438.

Filed
April 22, 2026
Annual meeting
June 2, 2026
Pay year
2025
Named executives
6
CEO total pay
$9.2M-6% vs prior year
CEO to median employee
37:1median $246,438
CEO pay in equity
85%$7.8M in awards
Prior say-on-pay support
96%of votes cast
CEO Target Bonus
550,200Expressed in US dollars
Say-on-Pay Support
96.3%From 2025 annual meeting
Median Employee Pay
$246,438Calculated for fiscal 2025
Net Capital Raised
$112.2MFrom at-the-market equity offering

How Mortimer was paid

$9.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary9%Stock awards19%Option awards66%Non-equity incentive6%All other compensation1%

Named executive officers

ExecutiveTotal
Ian MortimerPresident and Chief Executive Officer$9,221,712
Thomas KellyChief Financial Officer$7,238,664
Darren ClineChief Commercial Officer$4,048,214
Andrea DiFabioChief Legal Officer and Corporate Secretary$3,062,790
Christopher KenneyChief Medical Officer$3,145,290
Sherry AulinFormer Chief Financial Officer$356,453

What changed and why

  • $9.2MIan Mortimer received a total compensation of $9,221,712 in 2025, representing a decrease from his 2024 total compensation.
  • 45%Variable non-equity cash bonuses for NEOs ranged from 45% to 70% of base salaries at target.
  • 96.3%The advisory vote on executive compensation received approximately 96.3% support at the previous annual meeting.
  • 51%Approximately 51% of the employee population was based in Canada and 49% in the United States.
  • Thomas Kelly joined as Chief Financial Officer and Darren Cline joined as Chief Commercial Officer during 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.